Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.
about
Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myelomaDynamism in gene expression across multiple studies.Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell linesMicroRNA: important player in the pathobiology of multiple myelomaTranscriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.Coordinated expression of tristetraprolin post-transcriptionally attenuates mitogenic induction of the oncogenic Ser/Thr kinase Pim-1.LINE-1 hypomethylation in blood and tissue samples as an epigenetic marker for cancer risk: a systematic review and meta-analysis.How I treat smoldering multiple myeloma.Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.Global epigenetic regulation of microRNAs in multiple myeloma.Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasoneInhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer.Promises and challenges of MicroRNA-based treatment of multiple myelomaThe expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma.Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.The molecular characterization and clinical management of multiple myeloma in the post-genome era.MUC1-C drives MYC in multiple myelomaHistone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.The genetic architecture of multiple myeloma.Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing.Association of Chromosomal Translocation and MiRNA Expression with The Pathogenesis of Multiple Myeloma.Number of expressed cancer/testis antigens identifies focal adhesion pathway genes as possible targets for multiple myeloma therapy.Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response.Forced KLF4 expression increases the generation of mature plasma cells and uncovers a network linked with plasma cell stagelncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcomeKLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models.Angiogenesis and multiple myeloma.Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients.In Silico Characterization of miRNA and Long Non-Coding RNA Interplay in Multiple Myeloma.Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome.The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma.Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma.Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma.Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies.
P2860
Q33607455-BF91F7CF-8806-42FE-8FEA-D491CDE44F70Q33675348-34039B0C-C456-4934-B0B3-39508C9596CFQ33742964-7426BB55-2F0A-497F-86D6-69F8DCBE05CCQ33786861-65E9BFEE-F54A-409E-B29B-9B4FE35627C1Q33978937-B69D347D-96CF-4B78-A689-D2601296B855Q34193713-90855F7B-5C64-4D2A-93F9-8107E5557455Q34282505-D9FBB068-F793-4FF9-B645-4CB4CCBA907AQ34580094-714FDCDA-3C20-4377-A514-7CD875BA47B6Q35097641-18ACFBCA-1D24-4CE5-B32D-ED9623A1B939Q35350129-305DB11D-B365-45B3-8A6C-116FF8C4C59CQ35485758-2F4F38F3-03AC-46B3-A40C-43E86BF6F3E6Q36368265-F94356EB-6AB2-4801-9BD2-0DDD62E65A80Q36384699-2F792AE2-D4FB-4028-BD2B-2526D14F8E75Q36390674-7161FC68-3BE4-49B1-8580-4C5FBEE699CBQ36419086-B81607DF-9B51-4713-BBA8-B378394F26BCQ36439245-22C2E82F-E4FE-48B1-B18E-F3A443127A1CQ36938798-17605865-3119-44F2-B721-09B0CFC36682Q36939043-357B80CB-37EE-4D98-B8B9-4E2486464913Q36942036-81FCF90D-9E1C-49CF-8BA1-D54F956641B0Q37277238-BDE66329-04DB-4D70-80E1-40F392C6ACFDQ37636576-BED2EEB3-3218-4C5D-A035-0699A4EFE941Q37716402-93760E81-76F9-4763-BAA9-08465A680F64Q37718836-C371C71B-EDAB-4094-8735-69C760679C12Q38101343-B6E610BF-11BC-45C6-B086-C733998909FCQ38190971-95BF27A4-B691-4A4F-B053-529838130781Q38343521-7FAC32E8-6EE3-4AFB-9259-C9D3FE888B61Q38759700-B65F82EF-E74C-47DC-85F2-265F57A7AD7EQ38768232-D555C3A6-0123-41FD-A424-8063EE433635Q38822886-38CB06F7-6E04-4F83-B2B6-3F81E70ECD46Q38860336-ACDE7C62-1737-463A-AE19-A1279C404F6FQ39696428-20B03D92-065D-4A0A-82C8-1A819685B581Q39923951-A5DA8E30-A98C-43C3-AFF6-32623D359F4EQ40046832-A4E3F814-871A-4C60-AE9D-9C907B392EA2Q43005372-95EDC106-127C-4D15-9278-BB192BC7F7B5Q49872152-FED96180-A9AE-40F0-81F1-D32CE5836695Q51806468-4C3288A0-98EE-44B7-BAF8-322ACB2E11EEQ51812800-0BCF8B7E-BBE9-420C-A19A-65B8F57198C6Q53766891-D226E02D-644B-4F6F-BCD7-FCDABF52E482Q55315738-9E307116-60A4-49F5-85C0-8C9C7EFCD689
P2860
Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Molecular classification of mu ...... tive for 14q32 translocations.
@en
Molecular classification of mu ...... tive for 14q32 translocations.
@nl
type
label
Molecular classification of mu ...... tive for 14q32 translocations.
@en
Molecular classification of mu ...... tive for 14q32 translocations.
@nl
prefLabel
Molecular classification of mu ...... tive for 14q32 translocations.
@en
Molecular classification of mu ...... tive for 14q32 translocations.
@nl
P2093
P50
P356
P1476
Molecular classification of mu ...... ative for 14q32 translocations
@en
P2093
Daniela Intini
Donata Verdelli
Fortunato Morabito
Luigia Lombardi
Vincenzo Callea
P304
P356
10.1200/JCO.2005.01.3870
P407
P577
2005-08-29T00:00:00Z